Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 120 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- BCL-2 Inhibitor, Chemotherapy, Hypomethylating Agents (HMA)
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1542
- NCT Identifier
- NCT05600894
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.